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Abstract
Background: Fibromyalgia is a painful, debilitating illness with a prevalence of 0.5-5.0% that affects women more than 
men. It has been shown that the diagnosis of fibromyalgia is associated with improved patient satisfaction and 
reduced healthcare utilization. This survey examined the patient journey to having their condition diagnosed and 
studied the impact of the condition on their life.
Methods: A questionnaire survey of 800 patients with fibromyalgia and 1622 physicians in 6 European countries, 
Mexico and South Korea. Patients were recruited via their physician.
Results: Over half the patients (61%) were aged 36-59 years, 84% were women, and the mean time since experiencing 
fibromyalgia symptoms was 6.5 years. Patients had experienced multiple fibromyalgia symptoms (mean of 7.3 out of 
14), with pain, fatigue, sleeping problems and concentration difficulties being the most commonly reported. Most 
patients rated their chronic widespread pain as moderate or severe and fibromyalgia symptoms were on average 
"fairly" to "very" disruptive, and had a "moderate" to "strong" impact on patients' lives. 22% were unable to work and 
25% were not able to work all the time because of their fibromyalgia. Patients waited on average almost a year after 
experiencing symptoms before presenting to a physician, and it took an average of 2.3 years and presenting to 3.7 
different physicians before receiving a diagnosis of fibromyalgia. Patients rated receiving a diagnosis as somewhat 
difficult on average and had difficulties communicating their symptoms to the physician. Over one third (35%) felt their 
chronic widespread pain was not well managed by their current treatment.
Conclusions: This survey provides further evidence that fibromyalgia is characterized by multiple symptoms and has a 
notable impact on quality of life and function. The diagnosis of fibromyalgia is delayed. Patients wait a significant 
period of time before presenting to a physician, adding to the prolonged time to diagnosis. Patients typically present 
with a multitude of symptoms, all resulting in a delay in diagnosis and eventual management. Helping clinicians to 
diagnose and manage patients with fibromyalgia should benefit both patients and funders of healthcare.
Background
Fibromyalgia is a chronic, painful condition, with world-
wide prevalence estimates ranging between 0.5% and
5.0% [1], that affects women approximately 7 times more
often than men [2]. According to the American College of
Rheumatology (ACR) classification criteria, fibromyalgia
is characterized by widespread pain in all four quadrants
of the body for at least 3 months, with pain on digital pal-
pation in at least 11 out of 18 tender points [3]. In addi-
tion to pain, patients also commonly report other
symptoms such as problems sleeping, fatigue, stiffness,
problems with concentration, headaches, migraine, par-
esthesias and irritable bowel or bladder [3,4]. Clinically
relevant levels of anxiety or depression have been identi-
fied in approximately one-third of patients [2,5]. Patients
with fibromyalgia have reduced quality of life and often
m a r k e d  d i s a b i l i t y  [ 4 , 6 ] .  P e o p l e  w i t h  f i b r o m y a l g i a  h a v e
been shown to have greater overall health status impair-
ment than those with other chronic pain conditions such
as rheumatoid arthritis, osteoporosis and osteoarthritis
[7].
Although fibromyalgia is the most common chronic
widespread pain condition, it is often underdiagnosed [8].
The diagnosis of fibromyalgia has been shown to increase
patient satisfaction [5] and reduce healthcare utilization
[9]. This international survey of fibromyalgia examines
the experience of patients, the impact of the disease on
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quality of life, time taken from symptom onset to diagno-
sis, and explores their journey to diagnosis. The survey
was conducted to provide descriptive data.
Methods
This survey of patients diagnosed with fibromyalgia was
conducted between February 25th and April 17th, 2008 in
eight countries; France, Germany, Italy, Mexico, The
Netherlands, South Korea, Spain, and the United King-
dom (UK). Patients were identified by physicians who
treated them for fibromyalgia; the recruiting physicians
either participated in a companion survey or were sam-
pled specifically for the purpose of recruiting fibromyal-
gia patients, but did not complete the physician survey.
Physicians who recruited patients were identified using
proprietary databases and physician directories. Patients
were compensated for completing the survey. As this was
a non-interventional survey, no ethical approval was
required nor sought.
In total, 681 patients (85%) were surveyed via telephone
interview using computer assisted telephone interview-
ing (CATI) technology. Face-to-face interviews using a
pen and paper survey were conducted in South Korea in
compliance with cultural norms (19 patients in Mexico
were interviewed face-to-face using CATI due to respon-
dents' preference). In South Korea, it is more considerate
to conduct such an interview (>15 minutes long) face-to-
face rather than by telephone. Further, face-to-face inter-
view generates more trust and some comfort level
between the respondent and interviewer which is partic-
ularly important in Asian cultures.
The English questionnaire was translated into all lan-
guages by an independent professional translation
agency, and then all translations were validated by
another independent translation agency. The local opera-
tors who administered the questionnaires also reviewed
the translations before collecting the data. The question-
naire, which took approximately 15 minutes to complete,
included questions about demographic information,
symptoms, the impact of fibromyalgia on aspects of their
life, treatment, and about interactions with healthcare
professionals. Questions included lists of possible
answers that were proctored and self-administered by the
patient. The survey is included in additional file 1-Survey
of patients with fibromyalgia. Specific details of questions
and responses are provided in the results below. Data
were processed and quality assured. A post-hoc statistical
analysis comparing variables between those patients who
reported being satisfied and not satisfied with treatment
was conducted. P values were based on z-test of column
proportions.
In addition, a survey of physicians in the eight countries
was conducted, which included questions about physi-
cian behaviors and perceptions related to fibromyalgia
diagnosis. In each country primary care physicians
(PCPs), rheumatologists, neurologists, psychiatrists and
pain specialists were surveyed.
Results
Patients
In total, 800 patients and 1622 physicians completed the
survey (100 patients, 100-103 PCPs and 100-103 special-
ists from each country). All patients confirmed that a
physician had diagnosed their fibromyalgia. The demo-
graphic characteristics were generally similar across the
eight countries. Overall, 84% of patients were women and
were distributed by age group as follows: 19% 18-35
years, 26% 36-44 years, 35% 45-59 years, 16% 60-74 years,
and 4% ≥75 years. In the Korean sample, there was a
higher percentage of men (23%) than in the other coun-
tries (range 12-17%). The mean time since first experi-
encing fibromyalgia symptoms was 6.5 years (range
across countries 4.5 years in Mexico to 8.4 years in Spain).
Symptoms
The mean number of symptoms associated with fibromy-
algia that patients had experienced at any time, from the
list of 14 symptoms, was 7.3 and was similar across coun-
tries. All but two of the patients surveyed reported at
least one pain symptom. Chronic widespread pain was
reported by 65% of patients with other painful symptoms
such as joint pain, headache and low back pain also being
reported by more than half the patients (Figure 1). Non-
painful symptoms including fatigue, sleeping problems,
and concentration difficulties were also reported by over
half the patients (Figure 1).
Impact
Patients rated the extent of disruption to their overall
quality of life from each of the symptoms they reported
experiencing, on a five-point Likert scale from 1 = not at
all disruptive to 5 = extremely disruptive. All symptoms
were rated as being very or extremely disruptive by over
half the patients who reported the symptom. Over 20% of
patients rated chronic widespread pain, headaches, joint
pain, low back pain, problems sleeping, stiffness, height-
ened sensitivity to touch and feelings of depression as
extremely disruptive (5, maximum score). Mean disrup-
tion scores for each symptom were similar across coun-
tries. Across all symptoms overall mean disruption scores
combined across countries ranged from 3.6 to 4.0 (Figure
1).
Patients who reported they had experienced chronic
widespread pain were probed further about their pain.
Overall, 17% said they experienced widespread pain every
day, 10% 4 or 5 days per week, 38% 2 or 3 days per week,
and 26% once per week; 8% responded less than once per
week. Patients were asked to rate the severity of chronicChoy et al. BMC Health Services Research 2010, 10:102
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widespread pain from fibromyalgia from 0 = no pain to
10 = worst possible pain. Chronic widespread pain was
rated as severe (a score of 7 to 10) by 70% of patients and
as moderate (a score of 4 to 6) by 28%.
Among those who had been employed for the last 12
months (n = 513), 48% had missed 10 or more working
days in the last 12 months because of their fibromyalgia.
A notable proportion of patients had their employment
adversely affected by fibromyalgia at some time (Figure
2). On average, fibromyalgia had a moderate to strong
impact on many aspects related to quality of life (Figure
3).
Diagnosis of fibromyalgia
Patients were asked how long ago they first noticed
symptoms of fibromyalgia and how long after noticing
symptoms did they wait before presenting to a doctor.
The mean time taken to present to a physician was 11.1
months (range across countries 4.6 months in the UK to
18 months in Mexico). In total, 29% of patients did not
present to a physician for their symptoms until at least 6
months after the symptoms were first experienced.
Patients were asked to respond to specific reasons as to
why they waited to present to a doctor. The most com-
mon reasons were that patients thought the symptoms
would resolve (74%), they could manage symptoms them-
selves (68%), they do not like receiving medications or
injections (54%), the symptoms were not sufficiently
severe (51%), and that they do not like going to the doctor
(51%). Overall, 38% of patients gave one of the reasons for
delaying presentation to a doctor as being afraid they
would not be taken seriously, 44% were concerned about
cost, 42% were too busy, and 29% found it difficult to
schedule an appointment.
From the first time a patient presented to a physician
about their fibromyalgia symptoms, the mean time to
receiving an actual diagnosis of fibromyalgia was 2.3
years, with most countries being in the range of 2.1 to 2.7
years. The exceptions were Spain (3.7 years) and South
Korea (0.6 years). The average number of physicians
patients presented their symptoms to, before receiving a
diagnosis of fibromyalgia was 3.7, with 38% of patients
Figure 1 Percentage of patients who reported experiencing each symptom listed and the mean disruption scores. Disruption rated on a five-
point scale from 1 = not at all disruptive, 2 = not very disruptive, 3 = fairly disruptive, 4 = very disruptive, 5 = extremely disruptive. Mean impact on 
QOL - higher score means greater impact.Choy et al. BMC Health Services Research 2010, 10:102
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Figure 2 Impact of fibromyalgia on employment and expenditure. Patients were asked to rate the direct affect of fibromyalgia on employment 
and expenditure.
Figure 3 Impact of fibromyalgia on aspects of life. 1 = no impact, 2 = slight impact, 3 = moderate impact, 4 = strong impact, 5 = very strong impact.Choy et al. BMC Health Services Research 2010, 10:102
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having presented to more than three physicians. Patients
rated their overall difficulty in receiving a fibromyalgia
diagnosis on a five-point Likert scale from 1 = very diffi-
cult to 5 = very easy, and the average score was 2.3,
approximating to somewhat difficult. After the first con-
sultation with a physician about their symptoms, patients
in Europe most commonly presented to PCPs (95-98%),
rheumatologists (62-72%), neurologists (51-61%), and
psychiatrists (21-32%) about their fibromyalgia. In
Europe the percentage of patients who presented to a
pain specialist ranged from 14% in Italy to 46% in the
Netherlands. Data on the types of physicians from Mex-
ico and Korea were quite different from the European
countries, due to quite different structures in their
healthcare systems.
At the time of the survey, patients were mostly being
treated by PCPs, rheumatologists and neurologists (not
mutually exclusive, and quite variable across countries).
In total, 83% of patients were making fibromyalgia-spe-
cific visits to a physician at least once per month with
30% visiting a physician twice a month, and 11% visiting a
physician three times a month. Overall, 59% of patients
agreed that they had found it difficult to communicate
their fibromyalgia to physicians. Patients' overall percep-
tions about some aspects of their experiences with physi-
cians and fibromyalgia were captured. The percentages of
patients who somewhat or strongly agreed with specific
statements are shown in figure 4. Approximately three
q u a r t e r s  o f  p a t i e n t s  r e p o r t e d  t h a t  d o c t o r s  n e e d e d  t o
spend more time and to focus more on symptoms to
diagnose fibromyalgia.
In the companion survey of physicians, responses were
obtained from 809 PCPs, 206 rheumatologists, 201 neu-
rologists, 204 psychiatrists, and 202 pain specialists (n =
1622). Among these physicians, 24% strongly agreed and
40% somewhat agreed that it is difficult for patients to
communicate symptoms of fibromyalgia to a physician.
When asked how easy or difficult it was to diagnose
fibromyalgia, 11% of physicians (12% of PCPs and 10% of
specialists) responded that it was very difficult, and 42%
of physicians (48% of PCPs and 35% of specialists)
responded that it was somewhat difficult. Of the physi-
cians surveyed, 45% (52% of PCPs and 39% of specialists)
were not aware of the ACR fibromyalgia classification cri-
teria [3]. Of those physicians who were aware of the ACR
criteria and have diagnosed fibromyalgia patients in the
past two years (n = 725), 26% did not use the ACR criteria
when diagnosing fibromyalgia in their clinical practice.
Treatment
Among the patients surveyed, 70% were using pain medi-
cations prescribed by the physician, 36% were using over
the counter analgesics, 28% were using sleep aids and 56%
were using other prescribed agents. Non-drug treatments
Figure 4 Patients who somewhat or strongly agreed with statements about physicians during fibromyalgia diagnosis and management. 
Patients rated statements about diagnosing and managing fibromyalgia 5 = strongly agree, 4 = somewhat agree, 3 = neither agree nor disagree, 2 = 
somewhat disagree, 1 = strongly disagree. * at least one experience.Choy et al. BMC Health Services Research 2010, 10:102
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were also commonly used with exercise (48%), relaxation
techniques (45%), and lifestyle changes (44%) being the
most frequently employed. Patients were asked to rate
how satisfied they were with the ability of their current
treatment to relieve fibromyalgia symptoms on a five-
point Likert scale from 1 = not at all satisfied to 5 =
extremely satisfied, with 3 representing fairly satisfied.
The mean score was 2.9 and was similar across countries.
Half of patients were fairly satisfied (50%) or very satisfied
(19%), although 28% were not very satisfied or not at all
satisfied. Chronic widespread pain was the most common
symptom that patients reported as not well managed by
their current treatment (35%), with fatigue, joint pain and
concentration difficulties each not being well managed in
22% of patients.
Relationship between treatment satisfaction, symptoms 
and treatment
Given that over one quarter of patients were not satisfied
with their treatment, we explored some of the questions
according to levels of treatment satisfaction to evaluate if
there were any particular features that distinguished
those who were satisfied from those who were not.
Patients who were less satisfied with their treatment, on
average experienced significantly more symptoms, rated
their chronic widespread pain as being significantly more
severe and disruptive and used significantly more treat-
ments to manage their disease (Table 1). Compared to
patients who were satisfied with their treatment, patients
not satisfied with their treatment presented to signifi-
cantly more physicians to receive a diagnosis and overall
reported that receiving a diagnosis of fibromyalgia was
more difficult (p < 0.05). In addition, the mean time to
receiving a diagnosis was significantly longer in those
who were less satisfied with their treatment (mean 3.1
years) compared to those who were satisfied (mean 1.4
years) (p < 0.05). Also, patients not satisfied with their
treatment were more likely to miss more than 40 days of
work, and/or more likely to claim that they have not been
able to work or can only work some time, and/or more
likely to lose their job due to fibromyalgia (p < 0.05).
Discussion
The results of this survey are from 800 patients and over
1600 physicians from eight different countries. The
patient demographics were consistent with fibromyalgia
patients in the general population. Although chronic
widespread pain was the dominant symptom, fibromyal-
gia patients also experienced multiple symptoms (mean
of 7.3 from a list of 14) in addition to pain. The most com-
monly reported symptoms were fatigue, problems sleep-
ing and concentration difficulties, a finding which is
consistent with other studies [6,10-12]. This survey of
patients also confirms the negative impact of fibromyal-
gia which was reflected in average scores on particular
aspects of life and function such as motivation, concen-
tration, mobility, personal relationship and hobbies. The
economic impact of fibromyalgia on employment was
also notable, with almost half missing at least 2 weeks
work in the last year because of their fibromyalgia, 22%
actually unable to work at all, and 25% not able to work all
of the time because of the condition. The findings of this
survey are corroborated by others [6].
The most significant result of this survey is the insight
into patients' journey to diagnosis. At the time of this sur-
vey, patients had been experiencing fibromyalgia symp-
t o m s  f o r  a n  a v e r a g e  o f  6 . 5  y e a r s .  B a s e d  o n  t h e i r  o w n
recollection, patients experienced symptoms for an aver-
age of 11 months before presenting to a physician. Care
should be taken when interpreting data on the time lag
between first symptoms and presentation to a physician,
as patients may have a history of short and transient epi-
sodes of pain and other symptoms before the develop-
ment of persistent symptoms. Some patients seem to
have a very precise time of onset of symptoms e.g. follow-
ing a traumatic event, whereas others may have a long
history of localized pain or other symptoms (personal
observations). The most common reason (74%) for wait-
ing to present to the doctor was the belief that symptoms
would resolve. Given that fibromyalgia symptoms may
appear but not persist throughout the day and that symp-
toms may fluctuate in severity, it is not surprising that
patients do wait some time before seeking help from a
physician. Half of the patients also waited to present to a
physician, because they did not like taking medications or
did not like going to the doctor, and 68% of patients
thought they could manage symptoms themselves. Based
on clinical experience, patients seek help from physicians
not because of their symptoms per se, but because they
have a poor quality of life that is a consequence of their
fibromyalgia symptoms and are seeking help to improve
quality of life. Patients may struggle for some time with
impaired quality of life before seeking help.
From the time patients recalled first presenting to the
doctor for their fibromyalgia symptoms, it took on aver-
age 2.3 years and presenting to 3.7 physicians before
receiving a diagnosis. Such a delay can contribute to
patient frustration, as White et al. showed that a diagno-
sis of fibromyalgia improves satisfaction [5]. Further-
more, this survey extends the result of previous research
in the UK showing that patients with fibromyalgia are
often referred to multiple specialists and have numerous
investigations before the diagnosis is established [9]. This
survey shows that delayed diagnosis is not unique for the
UK but also occurs across other countries and cultures.
Importantly, the previous UK study showed that the diag-
nosis of fibromyalgia reduced healthcare utilization
including referrals and investigations [9]. Hence educat-Choy et al. BMC Health Services Research 2010, 10:102
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Table 1: Fibromyalgia characteristics and treatment utilization among those satisfied and not satisfied with their current 
treatment
Group A Group B
Not satisfied
Patients with satisfaction 
score 1 or 2 (n = 223)
Satisfied
Patients with satisfaction 
score 4 or 5 (n = 168)
P Value
Mean time since first 
experiencing symptoms
7.3 years 5.5 years <0.05
% of patients taking 
prescription pain medications
72% 60% <0.05
% of patients taking OTC pain 
medicines
38% 33% NS
% of patients taking other 
drugs prescribed by physician
52% 54% NS
Average number of symptoms 
experienced
8.4 6.4 <0.05
Chronic widespread pain 
extremely or very disruptive
87% 59% <0.05
Severity of chronic 
widespread pain
7.6 6.8 <0.05
Time lag between symptoms 
and seeing a physician
16.2 months 9.8 months NS
Time lag between seeing a 
physician and receiving a 
diagnosis
3.1 years 1.4 years <0.05
Average number of physicians 
seen to receive diagnosis
4.1 3.2 <0.05
Perceived difficulty in 
receiving diagnosis very or 
somewhat difficult
72% 47% <0.05
Missed more than 40 days of 
work
19% 10% <0.05
Unable to work due to 
fibromyalgia
36% 16% <0.05
Can only work some time due 
to fibromyalgia
35% 21% <0.05Choy et al. BMC Health Services Research 2010, 10:102
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ing clinicians on the recognition and diagnosis of fibro-
myalgia would benefit both patients and healthcare
providers. Therefore, it is important to understand why
the diagnosis of fibromyalgia is delayed. Several potential
factors are revealed by this survey.
First, over half the patients in this survey found it diffi-
cult to communicate with their physician, and most felt
that doctors needed to focus more on symptoms and
spend more time with patients to reach a diagnosis.
Therefore, multiple symptoms compounded by limited
consultation time may be an important factor. Second,
many physicians are not aware of the ACR criteria. In a
small percentage of those who are aware of the ACR cri-
teria and have diagnosed fibromyalgia patients in the past
two years, the ACR criteria are not used in routine clini-
cal practice. Better medical education to improve knowl-
edge and application of the ACR criteria may reduce
delay in the diagnosis of fibromyalgia. Third, ACR criteria
recognize pain and tender points but ignore the other
fibromyalgia symptoms. This could lead to confusion.
Improving the diagnostic criteria may help to circumvent
this problem.
An important limitation of all opinion research, and
this study is not an exception, is that respondents may not
perfectly well recall their experiences and feelings.
Respondents' feelings, attitudes and perceptions are sub-
ject to some potential changes in the course of time. The
survey provides a snapshot of the respondents' experi-
ences and does not seek to address how these might have
c h a n g e d  l o n g i t u d i n a l l y .  W e  s o u g h t  t o  e n s u r e  t h a t  t h e
diagnosis of fibromyalgia was not entirely dependent on
the patients' recollection, by including patients who were
diagnosed with fibromyalgia by a physician. The main
reason patients were recruited through their physicians,
rather than by random sampling as is sometimes the case
with such research, was to ensure that only patients who
were indeed diagnosed with fibromyalgia by their physi-
cians were interviewed.
Conclusion
This survey of 800 patients with fibromyalgia from eight
countries provides further evidence that fibromyalgia is
characterized by multiple symptoms, including pain, with
a notable impact on quality of life and function. Current
treatment regimens are not satisfactory for a substantial
proportion of patents. Patients may experience symp-
toms for some time before seeking the help of physicians.
Patient experiences suggest that physicians find diagnosis
difficult and that physicians need to spend more time
w i t h  p a t i e n t s  t o  d i a g n o s e  f i b r o m y a l g i a .  P a t i e n t s  w h o
reported dissatisfaction with treatment also reported
waiting longer to receive a work-up, diagnosis and care
for their fibromyalgia. By the time the patient presents to
the physician who actually diagnosed their condition, the
fibromyalgia journey has already begun (on average over
2 years). The association between chronicity of symp-
toms and worse response to treatment suggests that ear-
lier diagnosis and treatment may lead to improved
treatment response and reduced impact of the condition.
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